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Abstract  
Background: Observational prospective cohort study of HIV-positive pregnant women and their 
infants in Ukraine.  
Methods: HIV-positive pregnant women diagnosed before/during pregnancy (including intrapartum) 
and delivering liveborn infants are eligible for enrolment in the European Collaborative Study, which 
enrols approximately 30% of all HIV-positive women delivering in Ukraine at seven sites. Data on 
8884 HIV-positive mother/liveborn infant pairs delivering from 2000-2012 were analysed. Poisson 
regression models were fitted to identify factors associated with preterm delivery (PTD, <37 weeks 
gestation), and small-for-gestational-age (SGA, below 10th percentile of birthweight-for-gestational-
age). 
Findings: Median maternal age was 26∙5 years (IQR 23∙1-30∙3), 10.7% had WHO stage 3/4 disease 
and 16∙8% had an injecting drug use (IDU) history. PTD prevalence was 8∙8% (780/8860, 95%CI 8∙2-
9∙4) overall and 8∙7% (77/889, 95%CI 6∙9-10∙7) among SGA infants. Factors associated with PTD were 
IDU history (Adjusted Incidence Risk Ratio (AIRR) 1·64, 95%CI 1·38-1·95), non-receipt of antenatal 
antiretroviral therapy (ART) or receipt of combination ART (cART) (vs. zidovudine monotherapy, AIRR 
2∙94 95%CI 2∙43-3∙57 and 1∙41 95%CI 1∙14-1∙73), WHO stage 4 HIV disease (vs. stage 1, AIRR 2∙42, 
95%CI 1∙71-3∙41) and social deprivation (AIRR 1∙38 95%CI 1·11-1·71 for most vs. least deprived 
groups). IDU history and social deprivation were associated with SGA (AIRR 1·39 95%CI 1∙16-1∙65 and 
1∙32 95%CI 1∙09-1∙61), as was non-receipt of ART or receipt of cART (1∙60 95%CI 1∙32-1∙94 and 1∙33 
95%CI 1∙12-1∙60). Neonatal mortality rate was 4∙62/1000; of 41 deceased neonates, 20 were 
preterm. 
Interpretation: Risk factors included HIV-specific (e.g. worse clinical status) factors and others shared 
by the general antenatal population (e.g. substance use). Findings highlight the importance of 
monitoring pregnancy outcomes in Ukraine, given increasing use of antenatal cART.  
Funding: EU Seventh Framework Programme (FP7/2007-2013) under EuroCoord grant agreement 
n°260694. Claire Thorne’s Wellcome Trust Research Career Development Fellowship 
(081082/Z/06/Z).  
Key Words: preterm birth; small for gestational age; antiretroviral therapy; pregnancy; social 
deprivation; Ukraine. 
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Introduction 
The HIV epidemic in Eastern Europe and Central Asia continues to grow, with 88% of the region’s 
new infections occurring in the Russian Federation and Ukraine1. Although injecting drug use (IDU) 
has driven the HIV epidemic in this region, heterosexual acquisition became the main transmission 
route in newly diagnosed individuals in Ukraine in 2008 and of 21,631 new HIV cases diagnosed in 
2013, 45% were in women2. Ukraine is a lower middle-income country and treatment scale-up has 
been slow3: around 50,000 people were receiving antiretroviral therapy (ART)4 by 2013, around half 
the total estimated to have treatment indications according to WHO 2010 guidelines1.  
In the general population in Ukraine, the maternal mortality rate is 25 per 100,000, and the infant 
mortality rate is 9 per 1000 live-births, with 75% of pregnant women having at least four antenatal 
care visits5, 6. Prevention of mother-to-child transmission (PMTCT) of HIV programmes started in 
2001 and included universal antenatal HIV testing and repeat testing in the third trimester, short-
course zidovudine monotherapy (ZDVm) and/or single dose nevirapine and provision of free infant 
formula 7, 8. Subsequently ZDVm was recommended from at least 28 weeks gestation, and by 2007 
the MTCT rate had fallen to around 7%7; in that year Ukraine adopted the World Health Organization 
(WHO) Option B strategy (triple combination antiretroviral therapy (ART) for all pregnant women 
regardless of clinical or immunological status)9. Current MTCT rates are 2-4%.2, 9 National guidelines 
recommend elective caesarean delivery for HIV-positive women with a viral load >1000 copies/ml 
but access to viral load monitoring has been limited,3 with substantial variation in mode of delivery 
between clinical centres7. 
Adverse birth outcomes such as low birth weight (LBW), preterm delivery (PTD) and small-for-
gestational-age (SGA) have multiple aetiologies which are not well understood10. Associated risk 
factors include short maternal height, low/high body mass index, uterine/placental abnormalities, 
illicit drug use, lower socioeconomic status (SES), smoking, unintended pregnancy, psycho-social 
stress, prior PTD, infections and multiple pregnancy10, 11. Some, but not all studies, have identified 
maternal HIV infection as a risk factor for PTD, LBW, and poor fetal growth, with greatest risk for 
those with symptomatic disease, or severe immunodeficiency12-14. Antenatal combination ART 
(cART) has been associated with increased risk of PTD in HIV-positive women in studies in Europe, 
the US and Africa14-17, whilst other studies found no association.  
Pregnancy outcomes other than vertical HIV transmission have not yet been investigated in HIV-
positive women in Ukraine, but characterisation of these outcomes over the course of the epidemic 
so far is important for identifying health priorities and for future work exploring the impact of 
specific PMTCT interventions. Here, we describe birth outcomes in a cohort of HIV-positive women 
delivering over a thirteen-year period and investigate risk factors for adverse birth outcomes.  
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 Materials and Methods 
The European Collaborative Study (ECS) in EuroCoord (www.EuroCoord.net) is a cohort study, 
established in Ukraine in 20007, in which HIV-infected pregnant women are enrolled and their 
infants prospectively followed according to a standard protocol. Women identified as HIV-infected 
before/during pregnancy or intrapartum and delivering a live-born infant are eligible to enrol with 
informed consent; linked anonymised data are collected on study-specific questionnaires, using 
study serial numbers. Information collected includes maternal socio-demographic and HIV-related 
characteristics, and delivery/infant characteristics. Infants are followed up to establish infection 
status.  
A sub-study was established to obtain longitudinal information on HIV-positive women after 
delivery: women were enrolled in five of the seven Ukraine ECS sites from December 2007 to 2012, 
with initial postnatal data collected around 3-6 months postpartum.  Data are anonymously linked to 
ECS data using study serial numbers. Variables collected relevant to investigation of birth outcomes 
included current smoking, and maternal height.  
Given increased risk of SGA and PTD in multiple pregnancies11, 236 mother-infant pairs from 117 
multiple pregnancies (115 twin pairs, 2 triplet sets) were excluded from analyses. The study 
population for this analysis was 8884 ECS mother-infant pairs, delivering to August 2012, of whom 
2188 women were also in the postnatal sub-study.  
 
Definitions 
Maternal HIV symptoms were reported according to WHO clinical staging. Maternal antenatal ART 
was categorised as ZDVm or cART (defined as ≥3 antiretroviral drugs). IDU history (use of injecting 
drugs at any time) was determined by self-report, clinical assessment, or presence of neonatal 
abstinence syndrome; we used IDU history (rather than current IDU) for all analyses to reflect that 
drug use is a chronic and relapsing condition, and that drug use during pregnancy is likely to be 
substantially under-reported. Heavy and light-moderate smoking were defined as ≥20 and 1-19 
cigarettes/day, respectively. Elective caesarean sections (CS) were those before rupture of 
membranes and onset of labour. Gestational age was reported to the nearest completed week 
based on ultrasound (coverage of which is around 95% in the general antenatal population in 
Ukraine18) or, if no ultrasound, last menstrual period. PTD was defined as delivery before 37 
completed gestational weeks; extreme/severe PTD as delivery at ≤31 completed weeks of gestation, 
and moderate/late PTD as 32-36 completed weeks10.  LBW was defined as birthweight <2500g. 
Infants were considered to be SGA if <10th percentile of birthweight-for-gestational age, and severely 
SGA if <3rd percentile. Neonatal mortality was defined as death in the first four weeks of life. An 
individual Social Deprivation Index (SDI)19 was created by combining three variables (age at leaving 
full-time education, marital status, and history of a sexual partner who injected drugs ‘IDU partner’). 
IDU partner was incorporated within the SDI to capture social disadvantage found among 
populations of IDUs at high risk for HIV acquisition, while maternal IDU was included in models 
separately as an important independent risk factor for adverse pregnancy outcomes. 
Statistical analysis 
Due to the lack of population reference data to characterise SGA  and severely SGA, we obtained 
percentiles for weight and gestational age based on fitting the 4-parameter Sinh-Arcsinh (SHASH) 
probability distribution  to  birthweights of the study population of 8884 mother-infant pairs20. This 
distribution belongs to the class of generalised additive models for location, scale, and shape 
(GAMLSS) which allows specifying  smooth linear predictors on each of the model’s parameters21. 
We used natural cubic splines with degrees of freedom specified by minimising Akaike’s information 
criterion (AIC). Models were fitted to obtain gender-specific centiles of weight-for-gestational-age. 
Final models were chosen based on the best approximation to the empirical 3rd (severe SGA), and 
10th (SGA) percentiles.  
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Given the relatively high prevalence of study outcomes, Poisson regression models with robust 
standard errors22 were fitted to derive unadjusted and adjusted incidence rate ratios (AIRR) in 
analyses. Factors previously found to be associated with the outcomes i.e. IDU history, social 
deprivation, parity, WHO stage, antenatal ART, maternal age at delivery, smoking status, and 
maternal height10, 15 and associated (p <0∙05) with PTD and/or SGA in univariable analyses were 
included in multivariable models, plus calendar time and centre as fixed effects.  Associations 
between birth outcomes, smoking, and maternal height were assessed in a sub-analysis using data 
on a subgroup of women enrolled in both the ECS and the postnatal cohort study. Multivariable 
models were based on complete-case analysis. 
Missing values of the variables defining  the SDI were imputed using the mi command in STATA and 
then correspondence analyses (CA)23 were performed in each of the ten imputed datasets. 
Sensitivity analyses were conducted using a non-imputed dataset. Weighted coordinates based on 
the percentage of inertia explained by the first and second CA coordinates in each of the imputed 
datasets were averaged and included in cluster analyses using k-means, which is a non-hierarchical 
method of defining groups. Use of three clusters minimised the AIC in multivariable models. Thus 
the final SDI was composed of three levels: least, more, and most deprived. Statistical analyses were 
conducted using R, version 2.15.2 (R Foundation for Statistical Computing, Vienna) and STATA 
version 13.0 (StataCorp, College Station, Texas). 
Role of funding source  
The sponsor of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the data in 
the study and had final responsibility for the decision to submit for publication. 
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Results 
Cohort characteristics 
Of 8884 mother-child pairs enrolled in the ECS in 2000-2012, median maternal age at delivery was 
26∙5 years, most women had WHO stage I disease, and 54% were nulliparous (Table 1). Almost all 
women were born in Ukraine (99∙5%, 8839/8851), 84∙0% (7292/8680) were married/cohabiting, and 
29∙3% (2526/8623) had an IDU partner. Overall 16∙8% (1474/8760) of women had an IDU history, 
significantly declining from 40∙4% (21/52) in 2000/01 to 26∙8% (64/239) in 2002/03, 14% (180/1287) 
in 2008/09, and 10% (110/1095) in 2011/12 (𝜒12
2
trend=221∙7, p<0∙0001). Around one-third 
(2951/8392) had been diagnosed as HIV-positive pre-pregnancy, 61∙1% (5131/8392) during 
pregnancy, and 3∙7% (310/8392) at delivery. Overall 83∙1% of women received antenatal ART, mostly 
initiated in the third trimester, although with a shift to earlier initiation over time: median 
gestational age at ART initiation was 34 weeks (IQR: 34-36) before 2005, 28 weeks (IQR: 26-30) in 
2005-2008, and 24 weeks (IQR: 22-28) in 2009-2012. The proportion of women receiving no 
antenatal ART declined significantly from 78% in 2000 to 52% in 2001 to 9% in 2012. Among the 
2949 women receiving cART, type of regimen was available for 2911 of whom most (89%, 2602) 
received a PI-based regimen (mainly lopinavir/ritonavir) with a zidovudine(ZDV)/lamivudine 
backbone; only 124 women received a tenofovir-containing regimen. Regarding the SDI, around one-
fifth of women were in the most deprived group (Table 1).  
Delivery characteristics and prevalence of PTD and SGA 
Of the 8884 singleton infants, 4474 (50∙8%) were male and two-thirds were delivered vaginally 
(Table 1).  Median birthweight was 3100g (interquartile range (IQR): 2750-3400) and 1092 (12∙3%) 
infants were LBW. Median gestational age was 39 weeks (IQR 38-40) and 8∙8% of deliveries 
(780/8860) were preterm, with 1∙2% (n=107) extreme/severe preterm and 7∙6% (n=673) 
moderate/late preterm. Prevalence of SGA was 10∙1% (889/8788); 9∙9% (77/780) among preterm 
infants and 10∙3% (812/8016) among term infants. Among all SGA infants, 29∙3% (260/889) were 
severely growth restricted (<3rd percentile) and 8∙7% (77/889) were preterm. Among the 780 PTDs, 
94 (12∙2%) were delivered by elective CS (median, 35 gestational weeks) and 86 (11∙2%) by 
emergency CS.  
Risk factors for PTD 
In univariable analyses (n=7329), factors associated with increased risk of PTD were WHO Stage 4, 
non-receipt of antenatal ART or receipt of cART (versus ZDVm), IDU history, being in the most 
socially deprived group, parity, and older age (Table 2). In multivariable analyses, non-receipt of 
antenatal ART and WHO stage 4 were each associated with a more than two-fold increased risk of 
PTD. The positive associations between PTD risk and IDU history, social deprivation, WHO stage 3 (vs 
WHO stage 1), cART use (vs ZDVm), increasing calendar time, and older maternal age also persisted 
after adjustment for other variables (Table 2). In a multivariable model excluding the 94 deliveries by 
elective CS at <37 weeks from the study population, calendar time was no longer associated with 
PTD (AIRR 1∙03 95%CI 0∙99-1∙06, p=0∙117), but other associations remained broadly the same. 
CD4 monitoring was not available in the earlier years of the study and is not included in our main 
multivariable model. However in a sub-analysis of 3119 women with an antenatal CD4 count 
available who delivered from 2008 onwards, those with a higher CD4 count had a lower risk of PTD 
(AIRR 0∙64, 95%CI 0∙47-0∙87 for CD4 count 351-500 cells/mm3 versus ≤350) and (AIRR 0∙73, 95%CI 
0∙55-0∙96 for CD4≥500 cells/mm3 versus ≤350) after adjusting for all other variables in the main 
multivariable model apart from WHO stage. The association between cART and PTD remained after 
adjusting for CD4 count (AIRR 1∙40, 95%CI 1∙02-1∙93, p=0∙035).  
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In the sub-analysis of women in the postnatal cohort in addition to the ECS (n=1662), heavy smoking 
as well as moderate smoking were associated with increased risk of PTD in univariable analyses (IRR 
2∙55, 95%CI 1∙79-3∙65, p<0∙0001 and IRR 1∙51, 95%CI 1∙03-2∙19, p=0.033 respectively versus non-
smokers). In a multivariable model which included smoking plus the variables included in the main 
adjusted model, heavy smoking (vs. non-smoking), and IDU history were associated with a two-fold 
increased risk of PTD (AIRR 2∙16, 95%CI 1∙34-3∙49, p=0∙002 and 2∙06 (95%CI 1∙40-3∙03, p<0∙0001 
respectively). There was an attenuation of the association between PTD and IDU after adjusting for 
smoking from AIRR 2∙55, 95%CI 1∙78-3∙67 to 2∙06, 95%CI 1∙40-3∙03, and in the association between 
PTD and SDI (most deprived) from AIRR 1∙35, 95%CI 0∙87-2∙08 to 1∙18, 95%CI 0∙77-1∙82 (vs least 
deprived group).   
Risk factors for SGA 
Factors associated with significantly increased risk of having an SGA infant in univariable analyses 
(n=7581) are shown in Table 3. In the multivariable analysis, factors remaining significantly 
associated with increased SGA risk were antenatal cART, and non-receipt of antenatal ART (vs. 
ZDVm), IDU history and being in the most deprived SDI group, after adjusting also for WHO stage, 
calendar time, maternal age, and study centre (Table 3).  
In the sub-analysis of women enrolled in the postnatal cohort (n=1515), only current heavy smoking 
and not moderate smoking was associated with an increased risk of SGA (IRR 1∙64, 95%CI 1∙12-2∙40, 
p=0∙011 vs. non-smokers and 1∙21 (0∙82-1∙79), p=0∙334 respectively), while taller maternal height 
was associated with decreased risk (IRR 0∙97, p=0∙042 per additional 5cm). After adjusting for the 
other variables in the main model, there was a decreased risk of SGA for taller women (AIRR 0∙97, 
95%CI 0∙94-1∙00, p=0∙030 per additional 5cm), while IDU history and current heavy smoking were no 
longer associated with increased SGA risk (AIRR 1∙24, 95%CI 0∙78-1∙98, p=0∙358 and AIRR 1∙58, 95%CI 
0∙94-2∙66, p=0∙087 respectively).  
In a second SGA sub-analysis examining birth outcomes among 2559 women who started cART 
during pregnancy and received one NRTI backbone throughout, those who received tenofovir 
(n=123) did not have a significantly increased risk of PTD, SGA or LBW compared with those on 
ZDV/lamivudine (n=2204) (AIRR 0∙83 95%CI 0∙38-1∙79, AIRR 1∙15 95%CI 0∙66-2∙02 and AIRR 1∙09 
95%CI 0∙65-1∙82 respectively, adjusted for factors in Table 3); however, statistical power was limited 
due to the small number of women who received tenofovir.  
In a sensitivity analysis for severe SGA (third percentile) (n=7581), receipt of no antenatal ART or 
antenatal cART (vs ZDVm) and IDU history were associated with increased risk of severe SGA (AIRR 
1∙96, 95%CI 1∙32-2∙90, p=0∙001 vs. ZDVm; AIRR 1∙52, 95% CI 1∙08-2∙12, p=0∙014 vs. ZDVm  and AIRR 
1∙64, 95%CI 1∙17-2∙31, p=0.005 vs. non-IDU, respectively). For the women with information on 
smoking status, heavy smoking was associated with increased risk of severe SGA (IRR 2∙14, 95%CI 
1∙05-4∙36, p=0.036). However, moderate smoking and maternal height were not associated with risk 
of severe SGA (IRR 1∙69, 95%CI 0∙85-3∙33 vs. non-smoking, p=0∙133 and IRR 1∙00, 95%CI 0∙95-1∙05 
per additional 5cm, p=0∙980 respectively).  
Neonatal mortality 
The neonatal mortality rate was 4∙62 per 1000 (41/8884, 95% CI 3∙31-6∙26) overall. Of the 41 
neonates who died, 20 (48∙8%) were delivered preterm (8 extreme/severe preterm, 12 
moderate/late preterm), and five (12∙5%) were SGA. The risk ratio for neonatal death was 9∙9 (95% 
CI 5∙4-18∙1) for preterm versus term delivery and 1∙27 (95% CI 0∙50-3∙23) for SGA versus appropriate 
weight for gestational age. 
Sensitivity analysis for the multiple imputation 
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Results from the sensitivity analysis conducted to evaluate the effect of imputation of missing data 
on SDI indicated that for the PTD outcome there was a 12% change for the more vs. least deprived 
estimate and a 4.5% change of the estimate for the most vs. least deprived after the multiple 
imputation. For the SGA outcome the change of the estimates was around 10% and 13% for the 
more vs. least deprived group and the most vs. least deprived group respectively. All estimates were 
consistent with the mi analysis in the direction of the effect. 
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Discussion   
In this cohort of HIV-positive pregnant women delivering in Ukraine in 2000-2012, 9% delivered 
preterm. The limited overlap between these and the 10% of infants who were SGA is consistent with 
largely separate aetiologies for duration of pregnancy and fetal growth restriction. Cumulative 
prevalence of SGA and PTD reached 17∙9% overall. Over this period, IDU has declined and coverage 
with antenatal ART has increased, particularly cART9, and we have documented a significant increase 
in PTD. 
Rates of PTD vary between and within populations, with estimates of around 6% in Europe, 11% in 
North America, 9% in Asia, and 12% in Africa24. Information on PTD rates in Ukraine and Eastern 
Europe is scarce: a PTD rate of 5∙2% was reported in around 3000 births in urban Ukraine in 1992-95 
(85% spontaneous)25, while in Russia PTD rates range from 8∙7% among 17,000 births in Murmansk 
in 2006-200726 to 12∙4% among all deliveries in Tula oblast in 200027. With respect to HIV-positive 
women, the overall PTD rate here (9%) is lower than that reported from studies in Russia (2004-08 – 
25%)28, France (2000-09 – 14%)29, the UK (1990-2005 – 13%), Latin America (2002-12 - 20%)30, and 
the USA (2008-2010 - 20%)16, reflecting differences in background rates as well as in characteristics 
of the study populations.  
We explored IDU history rather than current IDU given that IDU is a chronic and recurring condition. 
In our cohort, these women mainly had a history of injecting home-made opiates31. In the main 
adjusted models, IDU history was associated with an increased risk of PTD and of having a SGA 
infant, consistent with other studies of HIV-positive15, 28, 29 and HIV-negative women, highlighting 
their need for a comprehensive package of care including opioid substitution therapy (as discussed 
previously in this cohort31). The 43% prevalence of smoking here is higher than that reported in a 
recent survey of reproductive-aged women in Ukraine (18% overall and 23% among 25-34 year-
olds)32, but consistent with higher rates among people living with HIV, including pregnant women14, 
33. The smoking prevalence reported here is higher than in other studies of HIV-positive pregnant 
women (20% in Western European, 25% in Latin American, and 14-17% in US cohorts)14, 16, 30, 33. 
However, we lacked data on smoking during pregnancy, using self-reported smoking postnatally in a 
sub-cohort as a proxy for antenatal tobacco exposure, which may have over-estimated smoking in 
pregnancy.  In sub-analysis incorporating smoking and maternal height, the 16% of women with 
heavy smoking had a significantly increased risk of PTD (AIRR 2∙15), consistent with the literature on 
the effect of smoking in shortening gestation in general11 and HIV-positive populations33.  
Maternal history of AIDS (WHO Stage 4) was associated with increased risk of PTD in adjusted 
analyses (AIRR 2∙42), but was not associated with having an SGA infant. Other studies have also 
identified symptomatic HIV disease, AIDS or severe immunodeficiency to be associated with 
increased risk of PTD15, 16, 29.  
The associations between antenatal ART and adverse birth outcomes need careful interpretation 
given the changing clinical practices over the study period, during which the national PMTCT policy 
transitioned from use of ZDVm and/or single dose nevirapine to cART (predominantly boosted 
protease inhibitor-based)7, 9. Although we adjusted for WHO stage and calendar time, we had limited 
ability to adjust for confounding by indication for ART receipt in pregnancy in our main analyses as 
we were unable to adjust for CD4 cell count (not routinely available until after 2006) and as reasons 
for prescription of antenatal cART have changed over time9. cART (vs ZDVm) remained associated 
with PTD in a sub-analyses which included antenatal CD4 count, although some of the increased risk 
of PTD may have been due to residual confounding caused by more severe HIV disease in this group. 
The significant association between lack of antenatal ART and PTD (AIRR 2∙94) may be partly 
explained by women delivering before having the opportunity to start ART, but also the likely 
correlation between non-receipt of ART and lack of or late presentation for antenatal care, a factor 
well known to be associated with PTD and SGA34. Our findings of an increased risk of PTD (AIRR 1∙40) 
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and SGA (AIRR 1∙33) associated with cART versus ZDVm here are consistent with other studies14-17. 
Preliminary data from the PROMISE trial indicated more severe pregnancy outcomes among infants 
exposed to tenofovir, emtricitabine and lopinavir/ritonavir than among those exposed to ZDV, 
lamivudine and lopinavir/ritonavir35. We detected no increased risk of PTD, SGA, or LBW among the 
small number of women receiving tenofovir-containing cART, but statistical power was limited. 
Evidence is growing of increased risks of PTD in women conceiving on cART and in those starting 
cART in pregnancy, with potentially different mechanisms16, 29, 30. We therefore plan further research 
focusing on timing and type of cART, particularly given the expanding use of cART in Ukraine in 
women before and during pregnancy9.  
The neonatal mortality rate was 4∙62 per 1000 livebirths, comparable to the national estimate of 5/ 
1000 in 2012. Comparison with other MTCT studies shows a similar rate in Latin America (4∙0/1000 
livebirths), another lower middle-income setting30, and slightly lower rate in the UK (3∙6/1000). PTD 
is the major cause of neonatal mortality worldwide and half the neonatal deaths here were in 
preterm infants.   
Our study is limited by the potential for confounding and bias, including social desirability bias, e.g. 
regarding reporting of IDU and smoking. We lacked data on hypertension, sexually transmitted 
infections, prior PTD, second-hand smoke exposure, alcohol use, timing of antenatal care initiation 
and psycho-social stressors and were unable to include these known risk factors in our analyses. We 
also lacked data on a comprehensive range of socioeconomic indicators (e.g. employment and 
housing status) for inclusion in the SDI. Regarding generalizability of our findings, our study enrols 
approximately 30% of all HIV-positive women delivering nationally. Our inclusion of the SDI 
strengthens our study, given associations between social deprivation and adverse pregnancy 
outcomes.  
In conclusion, in this large study of HIV-positive pregnant women, we have identified risk factors for 
PTD and SGA, some directly related to HIV infection, such as poor clinical status, and others shared 
by the general antenatal population, such as substance use and social deprivation. There are around 
4000 deliveries to HIV-positive women in Ukraine annually2. Based on our findings, we can estimate 
that annually approximately 720 infants born to HIV-positive women will be preterm and/or SGA and 
18 will die in the neonatal period; around 80-160 infants will be HIV-infected (one-fifth of whom will 
be preterm) based on current MTCT rates of 2-4%2, 9, although this will decrease with increasing roll-
out of antenatal cART for all HIV-positive pregnant women. There is focus on elimination of new 
infant HIV infections in Europe and globally1. Our findings indicate the importance of ensuring that 
on-going efforts to improve perinatal outcomes in Ukraine in general are extended to HIV-positive 
women. The association between antenatal cART and PTD in this population where cART has been 
available for PMTCT since 2007 requires further research and ongoing monitoring of pregnancy 
outcomes in the context of increasing use of cART.  
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Table 1. Maternal socio-demographic and clinical characteristics, (n=8884) 
  n (%) 
Maternal age (years) , n=8863   
≤ 18 140 (1∙6) 
18 – 26 4587 (51∙8) 
27- 34 3475 (39∙2) 
≥35 661 (7∙5) 
WHO stage, n=7741   
Stage 1 6444 (83∙2) 
Stage 2 465 (6∙0) 
Stage 3 734 (9∙5) 
Stage 4 98 (1∙3) 
Parity, n=8488   
Nulliparous 4592 (54∙1) 
Primiparous 2812 (33∙1) 
Multiparous 1084 (12∙8) 
Maternal ethnicity, n=8824   
White 8694 (98∙5) 
Other 130 (1∙5) 
Marital status, n=8680   
Single 1388 (16∙0) 
Married 3790 (43∙7) 
Cohabiting 3502 (40∙4) 
History of IDU, n=8760   
Yes 1474 (16∙8) 
No 7286 (83∙2) 
Partner history of IDU, n=8623   
Yes 2526  (29∙3) 
No 6097 (70∙7) 
Timing of HIV diagnosis, n=8392   
Pre pregnancy 2951 (35∙2) 
1st trimester 1623 (19∙3) 
2nd trimester 2291 (27∙3) 
3rd trimester 1217 (14∙5) 
At delivery 310 (3∙7) 
Received ART during pregnancy, n=8856   
Yes 7348 (83∙1) 
No 1497 (16∙9) 
Type of antenatal ART, n=8842   
None 1497 (16∙9) 
ZDV monotherapy 4396 (49∙7) 
cART 2949 (33∙4) 
Timing of ART initiation, n=7282   
Pre-pregnancy 252 (3∙5) 
1st trimester 105 (1∙4) 
2nd trimester 3330 (45∙7) 
3rd trimester 3595 (49∙4) 
Social Deprivation Index, n=8884   
Least deprived 4141 (46∙6) 
More deprived 2833 (31∙9) 
Most deprived 1910 (21∙5) 
15 
 
Delivery mode, n=8824   
Elective caesarean section 2619 (29∙6) 
Emergency caesarean section 344 (4∙0) 
Vaginal 5861 (66∙4) 
Smoking status1, n=2078   
Non smoker 1175 (56∙5) 
Light to moderate smoker 569 (27∙4) 
Heavy smoker (≥20 cigarettes per day) 334 (16∙1) 
Abbreviations: IDU: Injecting drug use, ART: Antiretroviral therapy, ZDV: Zidovudine, cART: Combination antiretroviral 
therapy. 
1Available in the postnatal sub-cohort only
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Table 2 Risk factors for preterm delivery (n=7328) 
  IRR 95% CI AIRR† 95% CI p-value 
History of IDU 
  
 
  
Yes vs. no 2∙30ˆ (1∙97, 2∙69) 1∙64 (1∙38, 1∙95) <0∙0001 
Social Deprivation Index      
More vs. least deprived 1∙16 (0∙98, 1∙40) 1∙19 (0∙99, 1∙44) 0∙067 
Most vs. least deprived 1∙51ˆ (1∙27, 1∙81) 1∙38 (1∙11, 1∙71) 0∙004 
Parity 
  
   
1 vs. 0  1∙22ˆ (1∙04, 1,44) 0∙97 (0∙82, 1∙15) 0∙737 
≥2 vs. 0  1∙53ˆ (1∙24, 1∙88) 1∙01 (0∙81, 1∙27) 0∙905 
WHO stage 
  
   
2 vs. 1 1∙02 (0∙73, 1∙42) 0∙85 (0∙60, 1∙21) 0∙366 
3 vs. 1 1∙66ˆ (1∙35, 2∙04) 1∙32 (1∙06, 1∙65) 0∙015 
4 vs. 1 3∙69ˆ (2∙59, 5∙26) 2∙42 (1∙71, 3∙41) <0∙0001 
Antenatal ART  
  
   
None vs. ZDV monotherapy 3∙45ˆ (2∙88, 4∙14) 2∙94 (2∙43, 3∙57) <0∙0001 
cART vs. ZDV monotherapy 1∙75ˆ (1∙46, 2∙10) 1∙40 (1∙14, 1∙73) 0∙001 
Calendar time per additional year 1∙02 (1∙00, 1∙05) 1∙04 (1∙01, 1∙07) 0∙009 
Maternal age (years)      
≤18 vs. 18-26  0∙90 (0∙43, 1∙86) 0∙84 (0∙42, 1∙71) 0∙650 
27-34 vs. 18-26 1∙50ˆ (1∙28, 1∙76) 1∙28 (1∙08, 1∙51) 0∙003 
≥35 vs. 18-26 1∙97ˆ (1∙55, 2∙51) 1∙55 (1∙20, 1∙99) 0∙001 
Abbreviations: IRR: Incidence risk ratio, AIRR: Adjusted incidence risk ratio, IDU: Injecting drug use, ART: Antiretroviral therapy, 
ZDV: Zidovudine, cART: Combination antiretroviral therapy. 
ˆSignificant in the univariable analysis 
†Adjusted for study centre, antenatal ART, IDU history, SDI, parity, WHO stage, maternal age and calendar year 
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Table 3 Risk factors for delivery of a SGA infant (n=7581) 
  IRR  95% CI AIRR† 95% CI p-value 
History of IDU 
  
   
Yes vs. No 1∙57ˆ (1∙35, 1∙83) 1∙39 (1∙16, 1∙65) <0∙0001 
Social Deprivation Index     
 
More vs. least deprived 1∙13 (0∙97, 1∙34) 1∙13 (0∙96, 1∙34) 0∙152 
Most vs. least deprived 1∙39ˆ (1∙17, 1∙63) 1∙32 (1∙09, 1∙61) 0∙006 
WHO stage 
    
 
2 vs. 1 1∙02 (0∙76, 1∙36) 0∙96 (0∙71, 1∙31) 0∙818 
3 vs. 1 1∙28ˆ (1∙04, 1∙58) 1∙12 (0∙89, 1∙40) 0∙335 
4 vs. 1 1∙73ˆ (1∙08, 2∙76) 1∙46 (0∙90, 2∙37) 0∙126 
Antenatal ART 
     
None vs. ZDVm 1∙87ˆ (1∙56, 2∙23) 1∙60 (1∙32, 1∙94) <0∙0001 
cART vs. ZDVm 1∙43ˆ (1∙23, 1∙66) 1∙33 (1∙12, 1∙60) 0∙002 
Calendar time per additional year 1∙02 (0∙99, 1∙04) 1∙01 (0∙98, 1∙04) 0∙523 
Maternal age (years)      
≤18 vs. 18-26  0∙74 (0∙38, 1∙46) 0∙71 (0∙36, 1∙39) 0∙312 
27-34 vs. 18-26 1∙12 (0∙98, 1∙30) 1∙03 (0∙89, 1∙19) 0∙730 
≥35 vs. 18-26 1∙35ˆ (1∙07, 1∙72) 1∙18 (0∙93, 1∙50) 0∙178 
Abbreviations: IRR: Incidence risk ratio, AIRR: Adjusted incidence risk ratio, IDU: Injecting drug use, ART: Antiretroviral 
therapy, ZDV: Zidovudine, cART: Combination antiretroviral therapy. 
ˆSignificant in the univariable analysis 
†Adjusted for study centre 
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Research in context 
 
Evidence before this study 
This is the first study of adverse birth outcomes among HIV-positive pregnant women in Ukraine. 
Published data on preterm delivery (PTD) rates in Eastern Europe are scarce but individual studies 
have reported rates from 5%-12% among the general population  and 25% among HIV-positive 
women in Russia. Concerns regarding PTD among HIV-positive women, first raised more than 20 
years ago, were initially focused on the impact of HIV and immunosuppression and then on 
combined antiretroviral therapy (cART) regimens, as well as traditional risk factors for PTD. 
Pregnancy outcomes among HIV-positive women need to be understood in the context of 
substantial variation between populations, to inform country-specific prevention of mother-to-child 
transmission (PMTCT) and maternal and child health programmes. 
 
Added value of this study 
In this study of nearly 9000 HIV-positive women in Ukraine delivering liveborn infants from 2000 to 
2012, 9% of deliveries were preterm with cumulative prevalence of PTD and SGA of 18%. Our results 
indicate that around 720 preterm and/or SGA infants were born to HIV-positive women annually at 
the end of this time period, with some risk factors directly related to HIV infection such as poor 
clinical status and cART use and others shared by the general antenatal population including 
substance use and social deprivation. The increase in PTD over the 13 years of this study, 
independently of cART scale-up since 2007, highlights the importance of further work to monitor 
outcomes and delineate contemporary risk factors, as antenatal cART coverage increases in this 
lower middle-income setting.  
 
Implications of all the available evidence 
This study spans pre-ART, zidovudine monotherapy and cART eras for HIV-positive pregnant women 
in Ukraine, addressing an important evidence gap on the evolution of and risk factors for adverse 
pregnancy outcomes in this population. We plan further research to assess the impact of antenatal 
cART as data accumulates on its use in Ukraine. 
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